文献速递临床试验与 GCP

SMILE研究:立体定向多分次放疗治疗非脊柱骨转移——多中心、开放标签III期随机对照试验研究方案

SMILE-stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial.
PubMed 文献 · Trials · 2024-11-13

SMILE研究为国际多中心III期随机对照试验,拟纳入162例非脊柱骨转移患者,随机接受3次立体定向体部放疗(每次9 Gy)或标准5次方案(每次7 Gy),于治疗后3个月评估疼痛反应、生活质量和转移灶控制,以检验3次方案在疼痛控制方面是否非劣于5次方案。

要点

  • SMILE研究比较3次SBRT(每次9 Gy)与5次SBRT(每次7 Gy)对非脊柱骨转移的疼痛控制。
  • 主要结局于治疗后3个月评估,包括疼痛反应、生活质量及转移灶控制。
  • 若3次方案非劣效,可能简化姑息放疗流程并减轻患者负担。

核心结论

  • 若3次SBRT方案显示非劣效,可能简化姑息治疗流程、减轻患者负担并树立新的治疗标准,体现以患者为中心的姑息放疗理念。

研究设计与样本

  • 国际多中心、开放标签III期随机对照试验,计划随机纳入162例非脊柱骨转移患者。
  • 干预为3次SBRT(每次9 Gy)对比标准5次SBRT(每次7 Gy)。
  • 采用意向性治疗和符合方案分析,并纳入数据完整性和缺失信息处理的适当措施。
  • 试验已于2022年5月3日在ClinicalTrials.gov前瞻性注册,标识号为NCT05406063。

主要发现

  • 治疗后3个月评估结局,聚焦疼痛反应、生活质量和转移灶控制。

关键数值与推荐

  • 3次方案为每次9 Gy,共3次;标准方案为每次7 Gy,共5次。
  • 主要评价指标为疼痛反应,于治疗后3个月评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SMILE study addresses a significant need in palliative oncology by evaluating the non-inferiority of a shortened, 3-fraction stereotactic body radiotherapy (SBRT) schedule against the traditional 5-fraction approach for non-spine bone metastases in terms of pain control. Optimizing SBRT could significantly enhance the quality of life for patients by providing effective pain relief while minimizing treatment sessions. METHODS: This international, multicenter phase III trial will randomize 162 patients to receive either a 3-fraction regimen (9 Gy per fraction) or a standard 5-fraction regimen (7 Gy per fraction). Outcomes, assessed at 3 months post-treatment, will focus on pain response, quality of life, and control of metastasis. With a hypothesis-driven design, the study will incorporate intent-to-treat and per-protocol analyses, incorporating appropriate measures for data integrity and handling of missing information. DISCUSSION: If the 3-fraction SBRT regimen demonstrates non-inferiority, it could streamline palliative care protocols, reduce patient burden, and set a new standard for treatment, reflecting a patient-centered approach in palliative radiation oncology. TRIAL REGISTRATION: The trial has been registered prospectively on ClinicalTrials.gov under the identifier NCT05406063, as of May 3, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Foerster R, Zwahlen DR, Schroeder C, et al. SMILE-stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial. Trials. 2024. PMID: 39538259. doi:10.1186/s13063-024-08608-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。